Guangzhou-based biotechnology company Magpie Pharmaceuticals announced on Monday that it has raised a nearly RMB100 million (US$14.8 million) series B financing round from Chinese venture capital firm Sangel Capital.
Chinese Biotech Firm Magpie Pharmaceuticals Raises Nearly $15M In Series B Round comes originally from China Money Network. All Rights Reserved....
This news article comes via China Money Network, who is the copyright owner of this information and news. FintekAsia.com has licensed the rights to this article and any republication or re-distribution in whole or in part of this content is strictly prohibited without the express consent of
